● Asset sales
● Research collaborations
Partnering deals in the life sciences depend upon a delicate ecosystem comprising licensors (typically smaller companies) and licensees (typically larger companies). The power balance between these two communities has ebbed and flowed over the years as needs and expectations have similarly shifted. One thing is for certain: partnering is the lifeblood of the life science industry and deal activity has never been higher.
This presents a substantial challenge for the prospective licensor: how do you get noticed? A large pharmaceutical company may review more than a thousand partnering proposals a year and getting your signal to be heard amongst all that noise is a huge challenge. This is where Longcross can help. It understands what ‘works’ and it knows who the key decision makers are and how they operate. Without this insight, a licensor can waste a significant amount of time and money spinning wheels.